Previously we showed that Brown Norway (BN/Mcw) rats are more resistant to myocardial ischemiareperfusion (I/R) injury than Dahl S (SS/Mcw) rats due to increased nitric oxide ( ⅐ NO) generation secondary to increased heat shock protein 90 (HSP90) association with endothelial nitric oxide synthase (NOS3). Here we determined whether increased resistance to I/R injury in BN/Mcw hearts is also related to tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH-1), the rate-limiting enzyme for BH4 synthesis. We observed that BH4 supplementation via sepiapterin (SP) and inhibition of GCH-1 via 2,4-diamino-6-hydroxypyrimidine (DAHP) differentially modulate cardioprotection and that SP alters the association of HSP90 with NOS3. BH4 levels were significantly higher and 7,8-dihydrobiopterin (BH2) levels were significantly lower in BN/Mcw than in SS/Mcw hearts. The BH4-to-BH2 ratio in BN/ Mcw was more than two times that in SS/Mcw hearts. After I/R, BH4 decreased and BH2 increased in hearts from both strains compared with their preischemia levels. However, the increase in BH2 in SS/Mcw hearts was significantly higher than in BN/Mcw hearts. These data indicate that BH4 mediates resistance to I/R by acting as a cofactor and enhancing HSP90-NOS3 association. nitric oxide; cardioprotection; guanosine 5Ј-triphosphate cyclohydrolase I NITRIC oxide ( ⅐NO) is a key signaling molecule in the cardiovascular system (3, 34). ⅐NO, both endogenous and exogenous, has been shown to increase cardioprotection during cardiac ischemia-reperfusion (I/R) injury in recent studies (2, 5, 18) .⅐NO is produced from the guanidine group of L-arginine in a NADPH-dependent reaction catalyzed by a family of nitric oxide synthase (NOS), which requires Ca 2ϩ /calmodulin, flavin adenine dinucleotide, flavin mononucleotide, and tetrahydrobiopterin (BH 4 ) as cofactors. Ischemia time-dependently decreases cardiac BH 4 content and endothelial NOS (NOS3) activity and increases NOS-derived superoxide (O 2
and decreased ⅐ NO in BN/Mcw hearts compared with controls but not in SS/Mcw hearts. SP increased the association of HSP90 with NOS3. These data indicate that BH4 mediates resistance to I/R by acting as a cofactor and enhancing HSP90-NOS3 association. nitric oxide; cardioprotection; guanosine 5Ј-triphosphate cyclohydrolase I NITRIC oxide ( ⅐NO) is a key signaling molecule in the cardiovascular system (3, 34) . ⅐NO, both endogenous and exogenous, has been shown to increase cardioprotection during cardiac ischemia-reperfusion (I/R) injury in recent studies (2, 5, 18) .⅐NO is produced from the guanidine group of L-arginine in a NADPH-dependent reaction catalyzed by a family of nitric oxide synthase (NOS), which requires Ca 2ϩ /calmodulin, flavin adenine dinucleotide, flavin mononucleotide, and tetrahydrobiopterin (BH 4 ) as cofactors. Ischemia time-dependently decreases cardiac BH 4 content and endothelial NOS (NOS3) activity and increases NOS-derived superoxide (O 2 •Ϫ ) production, which is believed to contribute to postischemic endothelial dysfunction and myocardial injury (7) . BH 4 supplementation has been shown to restore endothelium-dependent coronary flow and decrease I/R injury in isolated perfused rat hearts (26, 32, 33) , whereas inhibiting BH 4 synthesis has been shown to increase I/R injury (13) . These observations suggest the importance of myocardial BH 4 bioavailability in cardioprotection and provide support for the notion that BH 4 may be a novel therapeutic target for treating I/R injury.
BH 4 is synthesized by either the de novo pathway or the salvage pathway (Fig. 1) . De novo synthesis starts with GTP in a Mg 2ϩ -, Zn 2ϩ -, and NADPH-dependent reaction to form 7,8-dihydroneopterin by GTP cyclohydrolase I (GCH-1), which is subsequently converted to 6-pyruvoyl-5,6,7,8-tetrahydropterin by 6-pyruvoyl-tetrahydropterin synthase (PTS), which is then converted to BH 4 by sepiapterin reductase (SR) (9) . GCH-1 is the rate-limiting enzyme in BH 4 synthesis. The salvage pathway metabolizes sepiapterin (SP) and 7,8-dihydrobiopterin (BH 2 ) to BH 4 by SR and dihydrofolate reductase (DHFR) (16) . Providing SP has been shown to effectively increase BH 4 content and thereby cardioprotection (26) . In contrast, selective inhibition of GCH-1 with 2,4-diamino-6-hydroxypyrimidine (DAHP) has been shown to either decrease BH 4 content and ⅐NO production in a coordinated manner or increase I/R injury in wide variety of experimental models (9, 12, 25, 31) . Accordingly, increasing BH 4 availability by modulating GCH-1 may be an effective way to restore ⅐NO-mediated endothelial function and to reduce I/R injury to the myocardium (22, 25) .
Previously, our laboratory showed that hearts from Brown Norway (BN/Mcw) rats were more resistant to ischemia than hearts from Dahl S (SS/Mcw) rats (1, 21) . More importantly, we showed that this increase in resistance to ischemia in hearts of BN/Mcw rats was related to an increase in the association of heat shock protein 90 (HSP90) with NOS3 and a subsequent increase in ⅐NO production in BN/Mcw rat hearts (21) . Because BH 4 is an essential cofactor for NOS3 and a decrease in BH 4 bioavailability is associated with uncoupled NOS3 activity and increased NOS3-dependent O 2
•Ϫ production, it is important to determine the role of BH 4 in altering resistance to I/R injury in these two rat strains. The goals of the present study were to determine 1) whether BH 4 
MATERIALS AND METHODS
Animals. All animal protocols were approved by the Institutional Animal Care and Use Committee of the Medical College of Wisconsin. Rats used in this study received humane care in compliance with the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health (NIH). Rats were maintained on a low-salt (0.4% NaCl) diet with unlimited access to water. Environmental influences were minimized by maintaining rats in identical housing conditions. Eight-week-old BN/Mcw and SS/Mcw male rats were obtained from Charles River (Wilmington, MA).
Langendorff isolated heart preparation and measurements. Hearts from BN/Mcw and SS/Mcw rats were isolated and perfused as previously described (21) . Briefly, rats were anesthetized and the hearts were excised and perfused in the Langendorff mode at a perfusion pressure equivalent to 80 mmHg. Perfusate and bath temperatures were maintained at 37.2 Ϯ 0.1°C using a thermostatically controlled water circulator (Lauda E100, Lauda Dr. R. Wobser, Pfarrstrasse, Germany). Left ventricular pressure was measured isovolumetrically with a transducer connected to a thin, saline-filled latex balloon inserted into the left ventricle through the mitral valve from an incision in the left atrium. Hearts were subjected to 35 min global ischemia followed by 120 min reperfusion. A three-way stopcock, located immediately above the site of cannulation, allowed the entire perfusate to be diverted away from the heart to produce global, no-flow ischemia. Reperfusion was achieved by repositioning the tap to allow perfusate to be delivered to the heart. The heart was immersed in nongassed physiological buffer solution within temperature-controlled chambers to maintain the myocardium at 37.2°C. Recovery was expressed as a ratio of the postischemic-reperfusion value over the predrug, preischemic value for developed pressure after 120 min of reperfusion. At the end of the experiments, the hearts were freeze-clamped and stored at Ϫ80°C until use for BH 4 analysis by HPLC or Western blot analysis. The protocol for perfusing isolated hearts with GCH-1 inhibitor DAHP (Sigma-Aldrich, St. Louis, MO) or the BH 4 precursor SP (Schircks Laboratories, Jona, Switzerland) is shown in Fig. 2 .
Measurement of BH 4 and BH2. The BH4 and BH2 levels were determined as described previously (6) . Briefly, 100-mg samples from heart tissue were lysed in 1 ml of 50 mM phosphate buffer (pH 2.6) containing 0.2 mM diethylenetriamine pentaacetic acid (DTPA; Sigma-Aldrich) and 1 mM 1,4-dithioerythritol (DTE; Sigma-Aldrich; freshly added) and then homogenized followed by centrifugation (12,500 rpm ϫ 10 min, 4°C). The supernatants were filtered through a 10-kDa cutoff column (Millipore, Billerica, MA). BH 4 and BH2 were quantified on a HPLC with an electrochemical detector (ESA Biosciences CoulArray system Model 542; Chelmsford, MA) using a Synergi Polar-RP column (Phenomenex, Torrance, CA) eluted with argon degassed 50 mM phosphate buffer (pH 2.6). Multichannel coulometric detection was set between 0 and 600 mV. One channel was set at Ϫ250 mV to verify the reversibility of BH 4 oxidative peak detection. Calibration curves were made by summation of peak areas collected at 0 and 150 mV for BH 4 and 280 and 365 mV for BH2. Intracellular concentrations of BH4 and BH2 were calculated using authentic BH 4 and BH2 standards. Cellular BH4 and BH2 levels were then normalized to cell protein concentrations.
Cardiomyocyte isolation. Myocytes were enzymatically isolated from BN/Mcw and SS/Mcw rats by a modified procedure by Mitra and Morad (14) . The hearts were excised, mounted on a Langendorff apparatus, and perfused retrogradely via the aorta with oxygenated isolation buffer containing (in mM) 110 Na ϩ , 3.8 K ϩ , 1.2 Mg 2ϩ , 25 HEPES, 113 Cl Ϫ , 1.2 H2PO4 Ϫ , and 11 glucose. After blood was washed out of the heart, the buffer was replaced with an enzyme solution containing 2.85 mg/ml collagenase type II (Gibco, Invitrogen, Carlsbad, CA), 0.1 mg/ml protease XIV (Sigma-Aldrich), and 0.1 mM Ca 2ϩ in the isolation buffer at pH 7.35. The temperature was maintained at 37°C. All solutions were continuously bubbled with 95% oxygen-5% carbon dioxide gas mixture. After 25 min of enzyme treatment, the ventricles were excised, minced, and incubated in the same enzyme solution for an additional 5 min in a shaker bath at 37°C. The cell suspension was filtered through a 200-m mesh and centrifuged (125 g ϫ 30 s; RT). The cell yield percentage (ratio of rods to rounded myocytes) was around 70 -80% (Supplemental Fig. 1 ; all supplemental material can be found with the online version of this article). Approximately 6 ϫ 10 5 rod shape myocytes were used for BH4 and BH2 assay. After isolation, the myocytes were pelleted and directly lysed in 1 ml of 50 mM phosphate buffer (pH 2.6) containing 0.2 mM DTPA and 1 mM DTE (freshly added) and then analyzed by HPLC for BH4 and BH2.
Real-time-PCR analysis for message levels of essential enzymes in BH4 biosynthesis. Total RNA was extracted from isolated myocytes or frozen heart tissue homogenates using TRIzol reagent (Invitrogen) and treated with DNase I via a DNA-Free kit (Ambion, Austin, TX). cDNA was generated from 1 g of total RNA using an iScriptTM cDNA Synthesis Kit (Bio-Rad, Hercules, CA). The primers for real-time-PCR were synthesized by Operon Biotechnologies (Huntsville, AL). The primer sequences for GCH-1 were 5Ј-GGCCGCTTACTCGTCCATCCT-3Ј (forward) and 5Ј-GGTCTC-CTGGTATCCCTTGGTGAA-3Ј (reverse); the sequences for PTS were 5Ј-GCGTTAAAGGGATTGTGAGGTCTGT-3Ј (forward) and 5Ј-CCGGGCTTCAATCCTCAGTTCT-3Ј (reverse); the sequences for SR were 5Ј-CCCACGTGGACTTCTATGAC-3Ј (forward) and 5Ј-CCAGCCCTAAGTTCTCTTCC-3Ј (reverse); and the sequences for DHFR were 5Ј-ACCAGGAAGCCATGAATCAG-3Ј (forward) and 5Ј-AGCAGTAGGACTTGGGAGCA-3Ј (reverse). Real-time-PCR was performed on an iCycler iQ real-time PCR instrument (Bio-Rad) in duplicates using iQTM SYBR Green Supermix (Bio-Rad) according to the manufacturer's instruction. The reaction for GAPDH mRNA was amplified for all samples as the internal reference. The amplification conditions were as follows: initial dena- Western blot analysis. Western blot analysis of homogenates from BN/Mcw and SS/Mcw hearts for GCH-1, SR, or DHFR expression was performed using the method described previously (19) . Briefly, samples was loaded into and separated by 12% SDS/PAGE. The proteins were transferred to a nitrocellulose membrane, which was then blocked with 5% nonfat milk-PBS buffer and incubated with primary antibodies overnight and secondary antibodies for 1 h. Bands of identity were visualized with a Super Signal West Pico kit (Pierce Biotechnology, Rockford, IL), and bands densities were quantified using UN-SCAN-IT software (Silk Scientific, Orem, UT). Antibodies specific for GCH-1 used in the study were kindly provided by Dr. Gabriele Werner-Felmayer (Division of Biological Chemistry, Biocentre, Innsbruck Medical University). DHFR and SR antibodies were purchased from Fitzgerald (Concord, MA) and Abnova (Taiwan), respectively.
Immunoprecipitation of NOS3. Heart tissue was homogenized in MOPS buffer containing 20 mM MOPS (pH 7.0), 2 mM EGTA, 5 mM EDTA, 30 mM sodium fluoride, 40 mM ␤-glycerophosphate (pH 7.2), 10 mM sodium pyrophosphate, 0.5% Nonidet P-40, protease inhibitor cocktail, and phosphatase inhibitor cocktail (Sigma-Aldrich). The lysates were precleared with protein A sepharose (Sigma-Aldrich) and then immunoprecipitated with monoclonal anti-NOS3 antibody (Biomol, Plymouth Meeting, PA; 3 g/400 g lysate protein) at 4°C overnight as described previously by our laboratory (19) . The next day, the protein A beads were added to the mixture and incubated at 4°C for 120 min. The beads were then spun down and washed four times with PBS buffer, and proteins were eluted and separated by SDS-PAGE. Proteins were electroblotted onto nitrocellulose membranes (Bio-Rad). The membrane was blocked in 5% nonfat dry milk in Tris-buffered saline-Tween and immunoblotted for NOS3 (Santa Cruz, CA) and HSP90 (Santa Cruz, CA). Proteins were detected by enhanced chemiluminescence with ECL reagents from Amersham (Pittsburgh, PA). Relative band densities of resulting autoradiograms were quantified with UN-SCAN-IT software.
Reactive oxygen species detection. Reactive oxygen species (ROS; O2
•Ϫ ) production was detected by using lucigenin-enhanced chemiluminescence. Coronary effluent was collected at 1 min of initial reperfusion time, 500 l were immediately taken to a 1.5-ml vial, and then 5 l (500 M) lucigenin (Sigma) were added for a final concentration of 5 M. The vial was placed in a luminometer (Turner Biosystems) to measure chemiluminescence for 5 min. The whole process was done in the dark room. The vial containing only lucigenin was read as background luminescence, and this value was subtracted from each sample. The generation of ROS was presented as relative light units.
H 2O2 and ⅐ NO detection. One milliliter of coronary effluent that was collected at the first minute of initial reperfusion time was immediately used for determination for concentration of ⅐ NO and H 2O2 by a ⅐ NO electrode and a H2O2 electrode (WPI, Sarasota, FL). Data were normalized by heart wet weight and coronary flow rate. Calibration of the H 2O2 and ⅐ NO electrode was performed according to the manufacturer's instructions by using 0.5, 1, 2, 4, and 8 M standard H 2O2 solution and NaNO2 and KI ϩ H2SO4 for ⅐ NO to generate known amounts of H2O2 and ⅐ NO. The calibration curves exhibited a linear correlation coefficient of 0.98 and 0.99.
Statistics. Data are expressed as means Ϯ SD and were analyzed by two-way ANOVA or by two-tailed t-test. A value of P Ͻ 0.05 was considered statistically significant. Fig. 3 4 than SS/Mcw rat hearts, we examined mRNA levels for GCH-1, PTS, SR, and DHFR, the key enzymes in both BH 4 de novo and salvage biosynthesis pathways. As shown in Fig. 5A , real-time PCR revealed that BN/Mcw rat hearts contained higher mRNA transcript levels for GCH-1 and PTS than did SS/Mcw rat hearts (1.93 Ϯ 0.17 and 1.27 Ϯ 0.04 vs. 1.29 Ϯ 0.29 and 1.09 Ϯ 0.07; P Ͻ 0.05; n ϭ 5/group). No differences in DHFR and SR mRNA transcripts were detected between the two strains (1.17 Ϯ 0.38 and 1.02 Ϯ 0.14 vs. 1.07 Ϯ 0.23 and 1.14 Ϯ 0.12). We further examined mRNA levels for GCH-1 and DHFR from freshly isolated cardiomyocytes; however, there were no differences in GCH-1 and DHFR mRNA observed in cardiomyocytes between BN/Mcw and SS/Mcw rats ( Fig. 5B ; n ϭ 5/group). Agarose gels for real-time PCR products showed only one clear band for GCH-1, PTS, SR, DHFR, and GAPDH, which indicated that the primers for these genes are very specific (supplemental Fig. 2) .
RESULTS

BH 4 and BH 2 levels in BN/Mcw and SS/Mcw rat hearts and cardiac myocytes. As shown in
GCH-1 protein levels. Western blot analysis showed that hearts from BN/Mcw rats have nearly 60% more GCH-1 than hearts from SS/Mcw rats (n ϭ 4/group, normalized to GAPDH protein levels; Fig. 6 ). There were no differences in DHFR and SR protein levels observed in these two rat strains (data not shown).
SP supplementation or DAHP inhibition of GCH-1 and resistance to myocardial ischemia. To determine whether BH 4 was responsible for increased resistance to ischemia in hearts from BN/Mcw rats compared with SS/Mcw rats, we perfused isolated hearts with either a GCH-1 inhibitor (DAHP, 2.5 mM) or a BH 4 donor (SP, 50 M) for 40 min before 35 min global ischemia. Hearts were then reperfused for 120 min. Left ventricular developed pressure (LVDP) and recovery of LVDP after 120 min reperfusion (expressed as a percentage of its predrug, preischemic value) were used to assess resistance to ischemia. LVDP and recovery of LVDP after I/R in untreated BN/Mcw rats were much higher than in SS/Mcw rats (64.4 Ϯ 4.6 mmHg and 59.6 Ϯ 4.1% vs. 37.8 Ϯ 3.9 mmHg and 37.1 Ϯ 4.3%; P Ͻ 0.01), which is consistent with previous findings from our laboratory (21) . SP increased LVDP and percent recovery of LVDP after I/R in SS/Mcw rat hearts (66.7 Ϯ 7.6 mmHg and 54.3 Ϯ 6.4%) but had no effect on BN/Mcw hearts (Fig. 7A) . DAHP decreased LVDP and recovery of LVDP in BN/Mcw hearts (39.9 Ϯ 5.2 mmHg and 38.2 Ϯ 4.4%) to that observed in untreated SS/Mcw hearts but did not further decrease recovery of LVDP in SS/Mcw rat hearts (Fig. 7B) .
Effects of SP and DAHP on cardiac BH 4 and BH 2 levels. To determine whether SP alters the levels of BH 4 and BH 2 in SS/Mcw rat hearts or DAHP in BN/Mcw rat hearts, BH 4 and BH 2 were measured at two time points: one is after perfusion of SP or DAHP for 40 min (right before ischemia) and the other one is after reperfusion for 120 min. The values at these time points were compared with the levels with untreated controls. After 40 min of SP perfusion in SS rat hearts, BH 4 increased but was not significantly different when compared with controls (Fig. 8A) . The BH 2 levels showed a huge increase (208 Ϯ 29 vs. 19.7 Ϯ 2.4 pmol/mg protein; P Ͻ 0.001) with SP treatment. After 120 min of reperfusion, BH 4 levels were higher in SP treatment group than in the controls (31 Ϯ 6 vs. 24 Ϯ 4 pmol/mg protein; P Ͻ 0.05) and BH 2 remained high after reperfusion although it was much lower compared with the preischemia value (68 Ϯ 10 vs. 208 Ϯ 29 pmol/mg protein; P Ͻ 0.001) in the SP treatment group. The BH 4 -to-BH 2 ratio decreased significantly after perfusion of SP, but the ratio was about the same between control and SP treated groups after 120 min reperfusion. In BN/Mcw rat hearts, DAHP did not alter BH 4 or BH 2 levels after 40 min perfusion (Fig. 8B) . However, after 120 min reperfusion the BH 4 levels were much lower and BH 2 levels were much higher in DAHP-treated hearts compared with the hearts from the control group (19.3 Ϯ 3.2, 59.5 Ϯ 12.2 vs. 35.4 Ϯ 4.6, 24.5 Ϯ 4.7 pmol/mg protein; P Ͻ 0.01). The BH 4 -to-BH 2 ratio was significantly lower in DAHPtreated hearts compared with control hearts after 120 min reperfusion (P Ͻ 0.01). These data confirm that BH 4 plays an important role in modulating resistance to ischemic injury in BN/Mcw and SS/Mcw rat hearts.
Effects of SP and DAHP treatment on HSP90 association with NOS3. A previous study from our laboratory demonstrated that the increased association of HSP90 with NOS3 is the major cellular mechanism by which BN/Mcw hearts produce more ⅐NO and less O 2
•Ϫ than SS/Mcw hearts to increase resistance to I/R injury compared with the SS/Mcw heart (21). Here we examined whether the supplement of SP or DAHP affected the association of HSP90 with NOS3. We immunoprecipitated NOS3 from heart homogenates of SS/Mcw hearts with or without SP treatment or BN/Mcw hearts with or without DAHP treatment and probed for NOS3 and HSP90 protein. Neither SP nor DAHP altered NOS3 protein levels. However, immunoblots of the immunoprecipitates showed that the amount of HSP90 bound to NOS3 was increased more than 60% in SP treated SS/Mcw hearts than nontreated hearts (Fig. 9 ). In contrast, the level of HSP90 associated with NOS3 in BN/Mcw rat hearts treated with DAHP significantly decreased compared with the level in BN/Mcw control hearts (supplemental Fig. 3) .
Change (Fig. 10) . The •Ϫ and H 2 O 2 levels were higher in SS/Mcw control hearts than that in BN/Mcw control hearts after I/R. After SP supplement ⅐NO levels significantly increased compared with control group in SS/Mcw rat hearts after I/R, whereas DAHP treatment significantly decreased the ⅐ NO levels in BN rat hearts compared with the control group after I/R. ⅐ NO levels in BN/Mcw control hearts were also higher than that in SS/ Mcw control hearts after I/R.
DISCUSSION
At the physiological level, NOS3 has been shown to play an important role in regulating vascular function (4, 24) . Our laboratory previously found that the response of the heart to an identical ischemic insult results in increased resistance to ischemia in the BN/Mcw rat compared with the SS/Mcw rat (21) . The underlying mechanism appeared to involve increased ⅐NO production in hearts from BN/Mcw rats compared with SS/Mcw rats mediated by an increase in HSP90 association with NOS3. Since the pteridine cofactor BH 4 has been shown to be an essential cofactor for maintaining NOS3 ⅐NO production (8, 10, 17, 29), here we examined the role of BH 4 and BH 4 biosynthesis in the mechanisms governing resistance to ischemia in both BN/Mcw and SS/Mcw rats. The major findings of this study are as follows. First, BH 4 levels were significantly higher and BH 2 levels were significantly lower in BN/Mcw rat hearts than in SS/Mcw rat hearts. The ratio of BH 4 to BH 2 in BN/Mcw rat hearts was more than two times the ratio in SS/Mcw rat hearts. Alterations in the absolute BH 4 and BH 2 levels, as well as the BH 4 -to-BH 2 ratio, were consistent with the recovery of cardiac function in BN/ Mcw and SS/Mcw rat hearts. Second, SP supplementation of SS/Mcw hearts or GCH-1 inhibition of BN/Mcw hearts increased and decreased resistance to I/R injury, respectively. Third, BN/Mcw rat hearts had more transcripts for GCH-1 than SS/Mcw rat hearts that together may have contributed to the higher BH 4 levels observed in these hearts. Finally, supplementation with the BH 4 precursor SP or DAHP, the inhibitor of GCH-1, elevated or decreased the association of HSP90 with NOS3, respectively. Our results clearly indicate that BH 4 and ongoing synthesis play crucial roles in modulating the susceptibility of hearts to I/R injury in BN/Mcw and SS/Mcw rats and that BH 4 mediates resistance to I/R by acting as a cofactor for NOS3 and enhancing HSP90-NOS3 association.
Reduced BH 4 likely represents an important cellular defect involved with both endothelial and cardiomyocyte dysfunction in hearts exposed to I/R (7). The role of BH 4 in NOS activity is particularly relevant to cardioprotection. Depletion of BH 4 not only prevents ⅐NO formation from NOS3 but also results in NOS3 uncoupling, which is characterized as NOS3 generating O 2
•Ϫ rather than ⅐NO (28). BH 4 deficiency resulting from reduced BH 4 biosynthesis or increased BH 4 oxidation to BH 2 , which is catalytically inactive, were shown to contribute to I/R injury (7) . Previously, our laboratory showed that a higher myocardial ⅐NO production and lower O 2
•Ϫ in BN/Mcw rats correlated to increased resistance to I/R injury compared with SS/Mcw rats (21) . We extrapolated on these findings, showing that the level of BH 4 in the heart is crucial for maintaining increased resistance to I/R injury in inbred strains of rats. Interestingly, the cellular source that affords different BH 4 levels apparently is not from cardiomyocytes. These data were logical since others have shown that vascular endothelium is a major source of BH 4 and⅐NO production in the myocardium under physiological conditions (23, 27) . However, the higher BH 2 levels in SS/Mcw cardiomyocytes, we observed here, indicate that cardiomyocytes from SS/Mcw rats are under greater oxidative stress than cardiomyocytes from BN/Mcw rats and also contribute to a lower BH 4 -to-BH 2 ratio in SS/ Mcw rat hearts. Indeed, an ox-blot (which detects the carbonylmodified proteins) of BN/Mcw and SS/Mcw rat heart homogenates revealed that the oxidative modification of proteins in SS/Mcw rat hearts was much higher than that in BN/Mcw rat hearts (supplemental Fig. 4 ). Recent studies in vascular biology have revealed the importance of the BH 4 -to-BH 2 ratio in determining whether BH 4 and BH 2 bind to NOS3. Since BH 4 and BH 2 bind to NOS3 with equal affinity, BH 2 rapidly and efficiently displaces BH 4 in NOS3, resulting in uncoupled NOS3 activity and decreased ⅐NO synthesis (8, 34) . Thus, in our study, in addition to lower BH 4 levels, the marked decrease in the BH 4 -to-BH 2 ratio in SS/Mcw rat hearts after I/R likely contributed to NOS uncoupling, increased ROS generation, and diminished recovery of cardiac function compared with BN/Mcw rat hearts.
Consistent with BH 4 levels in hearts, real-time PCR data showed that BN/Mcw rat hearts contained higher mRNA transcripts for GCH-1 and PTS than did SS/Mcw rat hearts. However, there were no differences of GCH-1 mRNA levels observed between BN/Mcw and SS/Mcw rat cardiomyocytes. Further studies to determine GCH-1 levels in endothelial cells and other cells in myocardium are needed to identify the exact source of the increase of GCH-1 in BN/Mcw rat hearts compared with SS/Mcw rat hearts and to explain the discrepancy between GCH-1 mRNA levels in the whole heart versus in isolated cardiomyocytes. Nevertheless, our results demonstrated that GCH-1 message levels in BN/Mcw and SS/Mcw rat hearts regulate ⅐NO production, and this regulation may be limited to vascular endothelium. Recently, Ionova et al. (11) reported that DHFR mRNA was not detectable in either unstimulated adult cardiac myocytes or after stimulation with inflammatory cytokines although the constitutive expression of DHFR was observed in neonate rat cardiomyocytes of the same Sprague-Dawley strain. In our study DHFR mRNA was detectable in freshly isolated BN/Mcw and SS/Mcw cardiomyocytes (without culture) but showed no differences between these two strains. Thus the salvage pathway, which has the functional capacity to convert BH 2 to BH 4 , does not play a crucial role in maintaining the high levels of BH 4 in BN/Mcw rat hearts.
In a recent review, increasing BH 4 availability by modulating GCH-1 has been suggested as a new strategy to protect the heart under conditions of stress, such as postinfarction remodeling, dilated myopathic remodeling, and hypertrophy (15) . It has been shown that the administration of exogenous BH 4 or SP, the precursor of BH 4 , restores ⅐NO production from NOS and enhances postischemic recovery of NOS-dependent coronary flow (7, 26 4 and BH 2 in these hearts after 120 min reperfusion. The results showed that DAHP increased BH 2 levels and decreased BH 4 levels in SS/Mcw rat hearts, whereas SP significantly increased BH 2 levels but did not change BH 4 levels in BN rat hearts (supplemental Fig. 5 ). Since the functional recovery of the SS/Mcw hearts was not altered by DAHP inhibition (Fig. 7) , these results indicated that NOS3 is fully uncoupled in SS/Mcw hearts after I/R injury; thus a further decrease in BH 4 -to-BH 2 ratio will not affect functional recovery, which was already significantly suppressed at the maximal level by I/R in SS/Mcw rat hearts. On the other hand, in BN/Mcw rat hearts, the BH 4 levels after I/R may still be sufficient for maintaining NOS3 function. BH 4 was not depleted enough to induce DHFR enzyme activity to convert BH 2 to BH 4 , thus SP supplementation could only result a higher BH 2 level. Consequently, SP was not able to increase functional recovery in BN/Mcw hearts where the function recovery was already high.
The cellular levels of BH 4 are a key factor in modulating NOS3 activity, ⅐NO production, O 2
•Ϫ production, and vascular reactivity in the postischemic heart. In our findings, O 2
•Ϫ and H 2 O 2 release from SS/Mcw rat hearts were significantly reduced by SP, whereas O 2
•Ϫ and H 2 O 2 release from BN/Mcw rat hearts were increased by DAHP. Moreover, there was more O 2
•Ϫ and H 2 O 2 released from SS/Mcw rat hearts than that from BN/Mcw rat hearts. After SP supplement ⅐ NO release was increased in SS/Mcw rat hearts. In contrast, DAHP significantly decreased ⅐NO production by BN/Mcw rat hearts compared with controls. Moreover, BN/Mcw rat hearts released more ⅐NO than SS/Mcw rat hearts. These results indeed confirm that there are good correlations between BH 4 levels and NOS-dependant ⅐NO and O 2
•Ϫ production. Previously, BH 4 was reported to structurally stabilize NOS dimers (30) , one of the mechanisms for promoting coupled NOS activity. Using Western blot analysis, we examined NOS3 dimers and monomers in SS/Mcw or BN/Mcw rats treated with SP or DAHP (supplemental Fig. 6 ). However, NOS3 dimer-to-monomer ratios were not altered in either SS/Mcw or BN/Mcw rat hearts after SP treatment. There was a slight decrease in NOS3 dimer-to-monomer ratios after SS/Mcw rat hearts were treated with DAHP. Thus these data suggest that NOS3 dimer-tomonomer ratios may not play a big role in NOS-coupled activity in our animal model.
A previous study from our laboratory indicated that proteinprotein interactions play an important role in regulating ⅐NO production with HSP90 modulating the balance of ⅐NO and O 2
•Ϫ generation from NOS3 (21) . An increased association of HSP90 with NOS3 is a major mechanism by which BN/Mcw hearts are more resistant to ischemia than SS/Mcw hearts. The advantage this mechanism affords is that the heart could rapidly respond to stressful conditions of oxygen deprivation, i.e., ischemia or hypoxia, without resorting to increased gene expression. The association of HSP90 with NOS3 may represent a universal mechanism by which the heart increases ⅐NO generation. An interesting finding in this study is that the association of NOS3 with HSP90 is increased in SS/Mcw rat hearts after SP supplementation compared with control hearts, whereas DAHP decreased the association of NOS3 with HSP90. The importance of this observation is that it demonstrates for the first time that BH 4 improves NOS3 activity and function by a mechanism beyond its role as a cofactor for NOS3. Furthermore, although some consider BH 4 to be important for improving vascular function, our data suggest that the mechanisms by which BH 4 and HSP90 increase NOS3-coupled activity may actually be interdependent.
In summary, our results show, for the first time, that BH 4 and GCH-1 differentially regulate resistance to I/R injury in the hearts of BN/Mcw and SS/Mcw rats. The mRNA transcription of GCH-1 regulates rates of BH 4 biosynthesis that are critical for increased ⅐NO production in BN/Mcw rat hearts, which affords increased resistance to myocardial ischemia. The different BH 4 -to-BH 2 ratios between BN/Mcw and SS/Mcw rat hearts also may explain the difference in the coupling state of NOS3 in these hearts. SS/Mcw rats have increased oxidation of BH 4 , which appears to contribute directly to decreased resistance to I/R injury in these hearts compared with the hearts from BN/Mcw rats. Furthermore, the mechanisms by which BH 4 and HSP90 regulate NOS3 activity and function to modulate cardioprotection may be interdependent.
